JP2020530777A5 - - Google Patents
Info
- Publication number
- JP2020530777A5 JP2020530777A5 JP2020520429A JP2020520429A JP2020530777A5 JP 2020530777 A5 JP2020530777 A5 JP 2020530777A5 JP 2020520429 A JP2020520429 A JP 2020520429A JP 2020520429 A JP2020520429 A JP 2020520429A JP 2020530777 A5 JP2020530777 A5 JP 2020530777A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- scfv domain
- quadruspecific
- binding specificity
- percentage homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524557P | 2017-06-25 | 2017-06-25 | |
| US62/524,557 | 2017-06-25 | ||
| PCT/US2018/039156 WO2019005639A2 (en) | 2017-06-25 | 2018-06-22 | MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530777A JP2020530777A (ja) | 2020-10-29 |
| JP2020530777A5 true JP2020530777A5 (cg-RX-API-DMAC7.html) | 2022-02-07 |
| JP7399852B2 JP7399852B2 (ja) | 2023-12-18 |
Family
ID=64742644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520429A Active JP7399852B2 (ja) | 2017-06-25 | 2018-06-22 | 多重特異性抗体とその作製及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11787863B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3645049A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7399852B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250024104A (cg-RX-API-DMAC7.html) |
| CN (4) | CN116199785A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018295118B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3068045A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL313468A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201912864SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019005639A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260008861A9 (en) * | 2017-06-25 | 2026-01-08 | Systimmune, Inc. | Anti-4-1bb antibodies and methods of making and using thereof |
| SG11201912865VA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| JP7383605B2 (ja) * | 2017-06-25 | 2023-11-20 | システィミューン, インク. | 抗pd-l1抗体とその作製及び使用方法 |
| TW201904588A (zh) * | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| AU2020279224B2 (en) | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| CN118580364A (zh) * | 2019-11-06 | 2024-09-03 | 西雅图免疫公司 | 制导和导航控制蛋白及其制备和使用方法 |
| EP3988568A1 (en) * | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| CN118974091A (zh) * | 2022-04-11 | 2024-11-15 | 阿斯利康(瑞典)有限公司 | T细胞结合蛋白 |
| CA3262028A1 (en) * | 2022-07-15 | 2025-06-13 | Abl Bio Inc. | Anti-ROR1 antibodies, bispecific antibodies containing it, and their uses |
| CN120813602A (zh) * | 2022-12-20 | 2025-10-17 | 英克特诺治疗公司 | 用于治疗癌症的组合疗法 |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
| CN116143934B (zh) * | 2023-03-21 | 2023-07-25 | 诺赛联合(北京)生物医学科技有限公司 | 一种干细胞外泌体提取试剂盒及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1392359T4 (da) | 2001-05-11 | 2013-06-10 | Ludwig Inst For Cancer Res Ltd | Specifikke bindingsproteiner og deres anvendelser. |
| CA2832136C (en) * | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| WO2007002223A2 (en) * | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| US8679502B2 (en) | 2007-11-13 | 2014-03-25 | Evec Inc. | Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same |
| US9365644B2 (en) * | 2008-04-23 | 2016-06-14 | Epitomics, Inc. | Anti-TNFα antibody |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| SG176219A1 (en) * | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| CN103906533A (zh) * | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
| PL3489261T3 (pl) * | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| US9732150B2 (en) * | 2013-03-14 | 2017-08-15 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
| HK1218549A1 (zh) | 2013-06-26 | 2017-02-24 | Numab Therapeutics AG | 新型抗体框架 |
| JP6693872B2 (ja) * | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス,インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| WO2015058861A1 (en) | 2013-10-25 | 2015-04-30 | Numab Ag | Bispecific constructs and their use in the treatment of various diseases |
| CA3265373A1 (en) * | 2014-02-20 | 2025-10-30 | H. Lundbeck A/S | Anti-acth antibodies and use thereof |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| US10428155B2 (en) * | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| EP3253790A4 (en) * | 2015-02-06 | 2018-07-25 | University of Maryland, Baltimore | Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection |
| CN104829733B (zh) * | 2015-05-25 | 2018-06-05 | 广州百暨基因科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
| JP6932700B2 (ja) * | 2015-09-15 | 2021-09-08 | アムジエン・インコーポレーテツド | 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用 |
| TW201904588A (zh) * | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
| SG11201912865VA (en) | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
-
2018
- 2018-06-22 US US16/615,122 patent/US11787863B2/en active Active
- 2018-06-22 SG SG11201912864SA patent/SG11201912864SA/en unknown
- 2018-06-22 KR KR1020257003259A patent/KR20250024104A/ko active Pending
- 2018-06-22 CN CN202310141321.2A patent/CN116199785A/zh active Pending
- 2018-06-22 IL IL313468A patent/IL313468A/en unknown
- 2018-06-22 EP EP18825293.6A patent/EP3645049A4/en active Pending
- 2018-06-22 IL IL271257A patent/IL271257B2/en unknown
- 2018-06-22 JP JP2020520429A patent/JP7399852B2/ja active Active
- 2018-06-22 CN CN201880039401.4A patent/CN110831973B/zh active Active
- 2018-06-22 KR KR1020207002328A patent/KR102763369B1/ko active Active
- 2018-06-22 CN CN202310141062.3A patent/CN116041530A/zh active Pending
- 2018-06-22 AU AU2018295118A patent/AU2018295118B2/en active Active
- 2018-06-22 CN CN202310922275.XA patent/CN116948035A/zh active Pending
- 2018-06-22 WO PCT/US2018/039156 patent/WO2019005639A2/en not_active Ceased
- 2018-06-22 CA CA3068045A patent/CA3068045A1/en active Pending
-
2025
- 2025-06-27 AU AU2025204860A patent/AU2025204860A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530306A5 (cg-RX-API-DMAC7.html) | ||
| JP2020529864A5 (cg-RX-API-DMAC7.html) | ||
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| CN117285641A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| JP2021519072A5 (cg-RX-API-DMAC7.html) | ||
| JP2022551081A (ja) | 癌処置のための多重特異性結合タンパク質 | |
| JP2021501575A (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| CN117222672A (zh) | 抗cldn4-抗cd137双特异性抗体 | |
| Li et al. | Advancing immunotherapy via multiple immune cells co-engagement | |
| HK40093821A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40088418A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40088417A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40111322A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40111323A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40097105A (en) | Bispecific antibodies and methods of making and using thereof | |
| WO2025064498A1 (en) | Affinity-modulated anti-cd45 x pd-1 and anti-cd43 x pd-1 bispecific antibodies to treat cancer and autoimmunity | |
| NZ760913B2 (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40109798A (en) | Guidance and navigation control proteins and method of making and using thereof | |
| TW202434635A (zh) | 多特異性抗體及其醫藥用途 | |
| HK40097671A (en) | Guidance and navigation control proteins and method of making and using thereof | |
| HK40097672A (en) | Guidance and navigation control proteins and method of making and using thereof | |
| HK40018991A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40019010A (en) | Multi-specific antibodies and methods of making and using thereof |